Trial Profile
A Phase II, Two-centre, Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Adult Subjects With Moderate to Severe Asthma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs ASM 8 (Primary)
- Indications Asthma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Syntara Limited
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 16 Nov 2011 New source identified and integrated (European Clinical Trials Database).
- 23 Jun 2011 Planned initiation date (May 2013) added as reported by ClinicalTrials.gov.